



Pharmaceuticals Limited

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,
Opp. SBI Executive Enclave, Banjara Hills,
Hyderabad - 500 034, Telangana, INDIA.
Tel : +91-40-2525 9999, Fax : +91-40-2525 9889
CIN : L24239TG1987PLC008066
Email: info@smspharma.com, www.smspharma.com

Date: 27th May, 2025

To
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001.

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Dear Sir/Madam,

Sub: Intimation of Investor's Conference Call

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing here with invitation for Investor's Conference Call, scheduled to be held on Monday, 2nd June, 2025 at 11:00 am, (IST), to discuss the Company's financial results and performance for the fourth quarter and year ended 31st March, 2025.

Please take into your records

Thanking you

Yours Faithfully

For SMS Pharmaceuticals Limited

Thirumalesh Tumma
Company Secretary



Hyderabad, May 27, 2025: SMS Pharmaceuticals Ltd, a diversified and integrated pharmaceutical company specialising in APIs and intermediates, will announce its results for the fourth quarter ended March 31, 2025, on Friday, May 30, 2025.

The results will also be available on the Company's website, <https://smspharma.com/>. The Company will hold an earnings conference on Monday, June 2, at 11 am IST, where senior management will discuss its results and performance.

SMS Pharmaceuticals Q4 & FY25 Earnings Call on Monday, June 2, 2025, at 11 am IST

Conference Dial-In Information:

Diamond Pass: Please click [here](#) to pre-register for the call

Universal Numbers	
	+91 22 6280 1254
	+91 22 7115 8043
Toll Free Numbers	
	Hong Kong – 800964448
	Singapore – 8001012045
	UK – 08081011573
	US – 18667462133

For any further information, please contact:

Company	Investor relations
SMS Pharmaceuticals Ltd	Eqspoint
Mr. Thirumalesh Tumma Email: complianceofficer@smspharma.com	Mr. Aditya Dutta Email: smspharma.IR@eqspoint.com